​

DexCom (DXCM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DXCM Stock Forecast

DexCom stock forecast is as follows: an average price target of $110.00 (represents a 27.27% upside from DXCM’s last price of $86.43) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.

DXCM Price Target

The average price target for DexCom (DXCM) is $110.00 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $120.00 to $100.00. This represents a potential 27.27% upside from DXCM's last price of $86.43.

DXCM Analyst Ratings

Buy

According to 13 Wall Street analysts, DexCom's rating consensus is 'Buy'. The analyst rating breakdown for DXCM stock is 1 'Strong Buy' (7.69%), 10 'Buy' (76.92%), 2 'Hold' (15.38%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

DexCom Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 08, 2024Shagun SinghRBC Capital$120.00$68.6274.88%38.84%
Aug 22, 2024Mathew BlackmanStifel Nicolaus$100.00$72.2838.35%15.70%
Aug 16, 2024Shagun SinghRBC Capital$130.00$72.3679.66%50.41%
Jul 29, 2024Matt MiksicBarclays$113.00$64.0076.56%30.74%
Jul 26, 2024Steven LichtmanOppenheimer$115.00$107.856.63%33.06%
Jul 26, 2024Matt O\'BrienPiper Sandler$90.00$63.2242.36%4.13%
Jul 26, 2024William PlovanicCanaccord Genuity$89.00$107.85-17.48%2.97%
Jul 26, 2024Shagun SinghRBC Capital$72.50$31.77128.20%-16.12%
Jul 12, 2024Mathew BlackmanStifel Nicolaus$132.00$112.6617.17%52.72%
Jun 03, 2024Steven LichtmanOppenheimer$150.00$115.2330.17%73.55%
May 30, 2024Issie KirbyRedburn Partners$130.00$127.641.85%50.41%
Mar 12, 2024Shagun SinghRBC Capital$165.00$134.4722.70%90.91%
Oct 27, 2023Steven LichtmanOppenheimer$122.00$88.9137.22%41.15%
Jan 06, 2023Morgan Stanley$131.00$114.4514.46%51.57%
Dec 26, 2022Stifel StifelStifel Nicolaus$130.00$111.4416.65%50.41%
Dec 12, 2022Citigroup$146.00$116.6425.18%68.92%
Oct 07, 2022Matt O'BrienPiper Sandler$120.00$95.2126.04%38.84%
Aug 01, 2022Raymond James$101.00$82.0823.05%16.86%
Jul 29, 2022Morgan Stanley$83.00$86.99-4.59%-3.97%
Jul 28, 2022Matt O'BrienPiper Sandler$110.00$86.9926.45%27.27%
Jul 15, 2022Lee HambrightBernstein$105.00$76.5037.25%21.49%
Jun 28, 2022Marie ThibaultBTIG$105.00$76.6037.08%21.49%
Jun 15, 2022Morgan Stanley$91.00$69.3131.29%5.29%
Jun 13, 2022Morgan Stanley$90.75$70.7428.29%5.00%
Jun 07, 2022Morgan Stanley$22.69$19.2717.70%-73.75%
May 03, 2022Mathew BlackmanStifel Nicolaus$32.50$24.7931.09%-62.40%
May 03, 2022Danielle AntalffyLeerink Partners$31.25$24.7926.05%-63.84%
Apr 29, 2022Raymond James$30.38$26.0516.59%-64.86%
Apr 29, 2022Piper Sandler$30.00$25.8316.16%-65.29%
Apr 21, 2022Marie ThibaultBTIG$35.00$31.0212.81%-59.50%
Mar 03, 2022Travis SteedBank of America Securities$31.25$26.5017.94%-63.84%
Feb 11, 2022Joanna WuenschCitigroup$39.38$26.2949.80%-54.44%
Jan 31, 2022Steven LichtmanOppenheimer$36.25$26.9134.73%-58.06%
Jan 19, 2022Jayson BedfordRaymond James$33.63$27.2023.61%-61.10%
Jan 19, 2022Larry BiegelsenWells Fargo$35.94$27.2032.11%-58.42%
Oct 29, 2021Kyle RoseCanaccord Genuity$39.06$38.950.29%-54.80%
Oct 29, 2021Ravi MisraBerenberg Bank$39.38$38.951.09%-54.44%
Oct 29, 2021Anthony PetroneJefferies$40.94$38.955.10%-52.64%
Oct 29, 2021Matthew TaylorUBS$41.25$38.955.90%-52.27%
Jul 30, 2021Chris CooleyStephens$34.13$32.225.91%-60.52%
Jun 09, 2021Robbie MarcusJ.P. Morgan$28.13$24.3815.38%-67.46%

The latest DexCom stock forecast, released on Oct 08, 2024 by Shagun Singh from RBC Capital, set a price target of $120.00, which represents a 74.88% increase from the stock price at the time of the forecast ($68.62), and a 38.84% increase from DXCM last price ($86.43).

DexCom Price Target by Period

1M3M12M
# Anlaysts--12
Avg Price Target--$117.21
Last Closing Price$86.43$86.43$86.43
Upside/Downside-100.00%-100.00%35.61%

In the current month, the average price target of DexCom stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to DexCom's last price of $86.43. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jan 08, 2025BernsteinOutperformOutperformHold
Dec 11, 2024CitigroupBuyBuyHold
Oct 22, 2024Piper SandlerOverweightOverweightHold
Oct 08, 2024RBC CapitalOutperformOutperformHold
Sep 24, 2024Piper SandlerOverweightOverweightHold
Aug 26, 2024Piper SandlerOverweightOverweightHold
Aug 23, 2024Wells FargoUnderperformUnderperformHold
Aug 23, 2024William BlairBuyBuyHold
Aug 16, 2024RBC CapitalOutperformOutperformHold
Jul 30, 2024Raymond JamesStrong BuyStrong BuyHold
Jul 29, 2024Wells FargoUnderperformUnderperformHold
Jul 29, 2024William BlairBuyBuyHold
Jul 29, 2024BarclaysEqual-WeightEqual-WeightHold
Jul 26, 2024William BlairOutperformOutperformHold
Jul 26, 2024OppenheimerOutperformOutperformHold
Jul 26, 2024Piper SandlerOverweightOverweightHold
Jul 26, 2024RBC CapitalOutperformOutperformHold
Jun 24, 2024Cowen & Co.BuyBuyHold
Jun 04, 2024BernsteinOutperformOutperformHold
Jun 03, 2024OppenheimerOutperformOutperformHold
Apr 15, 2024BTIGBuyBuyHold
Mar 25, 2024CitigroupBuyBuyHold
Mar 12, 2024RBC CapitalOutperformInitialise
Feb 09, 2024William BlairOutperformOutperformHold
Oct 27, 2023OppenheimerOutperformOutperformHold
Apr 28, 2023CitigroupBuyBuyHold
Apr 17, 2023Raymond JamesOutperformStrong BuyUpgrade
Jan 11, 2023Piper SandlerOverweightOverweightHold
Jan 06, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Dec 12, 2022CitigroupBuyBuyHold
Oct 07, 2022Piper SandlerOverweightOverweightHold
Aug 01, 2022Raymond JamesOutperformOutperformHold
Jul 29, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jul 28, 2022Piper SandlerOverweightOverweightHold
Jul 15, 2022BernsteinOutperformInitialise
Jun 24, 2022BTIGBuyBuyHold
Jun 07, 2022Morgan StanleyEqual-WeightEqual-WeightHold
May 17, 2022CitigroupBuyBuyHold
Apr 29, 2022Raymond JamesOutperformOutperformHold
Apr 29, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Apr 29, 2022Piper SandlerOverweightOverweightHold
Apr 29, 2022SVB LeerinkOutperformOutperformHold
Apr 21, 2022BTIGBuyBuyHold
Jul 01, 2021StephensOverweightOverweightHold

DexCom's last stock rating was published by Bernstein on Jan 08, 2025. The company gave DXCM a "Outperform" rating, the same as its previous rate.

DexCom Financial Forecast

DexCom Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$1.03B$975.00M$871.30M$741.50M$815.20M$769.60M$696.20M$628.80M$698.20M$650.20M$595.10M$505.00M$568.90M$500.90M$451.80M$405.10M$462.80M$396.30M
Avg Forecast$1.45B$1.34B$1.29B$1.19B$1.27B$1.17B$1.13B$1.03B$1.10B$990.44M$1.04B$909.93M$1.02B$939.64M$841.16M$720.71M$810.10M$751.80M$697.50M$623.87M$697.47M$618.65M$551.67M$486.59M$553.01M$500.90M$416.62M$358.55M$441.02M$347.89M
High Forecast$1.50B$1.38B$1.33B$1.23B$1.31B$1.21B$1.16B$1.06B$1.11B$991.10M$1.04B$909.93M$1.05B$948.40M$866.97M$742.82M$838.93M$751.80M$697.50M$623.87M$697.47M$618.65M$551.67M$486.59M$553.01M$500.90M$416.62M$358.55M$441.02M$347.89M
Low Forecast$1.42B$1.31B$1.27B$1.17B$1.25B$1.15B$1.11B$1.02B$1.08B$989.78M$1.04B$909.93M$994.92M$931.05M$824.27M$706.23M$792.14M$751.80M$697.50M$623.87M$697.47M$618.65M$551.67M$486.59M$553.01M$500.90M$416.62M$358.55M$441.02M$347.89M
# Analysts6446437912611318159101681099139910101099
Surprise %------------1.02%1.04%1.04%1.03%1.01%1.02%1.00%1.01%1.00%1.05%1.08%1.04%1.03%1.00%1.08%1.13%1.05%1.14%

DexCom's average Quarter revenue forecast for Mar 24 based on 1 analysts is $909.93M, with a low forecast of $909.93M, and a high forecast of $909.93M. DXCM's average Quarter revenue forecast represents a -12.04% decrease compared to the company's last Quarter revenue of $1.03B (Dec 23).

DexCom EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts6446437912611318159101681099139910101099
EBITDA------------$303.60M$207.20M$128.10M$110.70M$139.70M$190.00M$123.60M$78.30M$44.30M$141.30M$125.40M$66.90M$126.30M$117.90M$81.80M$50.80M$123.90M$73.80M
Avg Forecast$273.27M$251.66M$243.77M$224.50M$239.25M$221.18M$212.82M$193.57M$207.67M$186.51M$195.31M$131.18M$191.19M$176.94M$158.40M$119.26M$58.93M$123.25M$114.35M$108.42M$114.35M$101.42M$90.44M$60.21M$90.66M$82.12M$68.30M$58.06M$72.30M$57.03M
High Forecast$281.66M$259.39M$251.25M$231.39M$246.59M$227.97M$219.35M$199.26M$209.55M$186.63M$195.31M$157.42M$197.06M$178.59M$163.26M$143.11M$70.72M$123.25M$114.35M$130.10M$114.35M$101.42M$90.44M$72.25M$90.66M$82.12M$68.30M$69.67M$72.30M$57.03M
Low Forecast$267.78M$246.61M$238.88M$219.99M$234.44M$216.74M$208.54M$191.67M$203.89M$186.38M$195.31M$104.95M$187.35M$175.32M$155.22M$95.41M$47.14M$123.25M$114.35M$86.73M$114.35M$101.42M$90.44M$48.17M$90.66M$82.12M$68.30M$46.45M$72.30M$57.03M
Surprise %------------1.59%1.17%0.81%0.93%2.37%1.54%1.08%0.72%0.39%1.39%1.39%1.11%1.39%1.44%1.20%0.88%1.71%1.29%

1 analysts predict DXCM's average Quarter EBITDA for Mar 24 to be $131.18M, with a high of $157.42M and a low of $104.95M. This is -56.79% lower than DexCom's previous annual EBITDA (Dec 23) of $303.60M.

DexCom Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts6446437912611318159101681099139910101099
Net Income------------$256.30M$120.70M$115.90M$48.60M$91.80M$101.20M$50.90M$97.30M$-19.40M$70.90M$62.90M$40.30M$355.20M$72.20M$46.30M$19.90M$92.70M$45.80M
Avg Forecast$311.85M$265.93M$237.55M$188.79M$257.20M$220.31M$197.03M$155.42M$205.33M$178.25M$158.40M$163.01M$176.68M$139.75M$92.64M$148.20M$-25.81M$101.91M$76.45M$134.72M$90.82M$67.66M$46.25M$36.27M$96.72M$66.79M$35.08M$22.74M$77.36M$20.85M
High Forecast$324.29M$276.54M$247.03M$196.32M$267.46M$229.10M$204.89M$189.02M$229.97M$178.34M$158.43M$195.62M$189.01M$189.07M$96.33M$177.83M$-20.65M$101.91M$76.45M$161.67M$90.82M$67.66M$46.25M$43.52M$96.72M$66.79M$35.08M$27.29M$77.36M$20.85M
Low Forecast$303.71M$258.99M$231.35M$183.86M$250.48M$214.56M$191.88M$126.01M$168.37M$178.15M$158.37M$130.41M$160.24M$106.87M$90.22M$118.56M$-30.97M$101.91M$76.45M$107.78M$90.82M$67.66M$46.25M$29.02M$96.72M$66.79M$35.08M$18.19M$77.36M$20.85M
Surprise %------------1.45%0.86%1.25%0.33%-3.56%0.99%0.67%0.72%-0.21%1.05%1.36%1.11%3.67%1.08%1.32%0.88%1.20%2.20%

DexCom's average Quarter net income forecast for Mar 24 is $163.01M, with a range of $130.41M to $195.62M. DXCM's average Quarter net income forecast represents a -36.40% decrease compared to the company's last Quarter net income of $256.30M (Dec 23).

DexCom SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts6446437912611318159101681099139910101099
SG&A------------$308.80M$284.70M$297.30M$294.60M$297.80M$234.60M$248.90M$220.90M$235.10M$199.80M$187.00M$188.60M$175.90M$158.60M$136.40M$149.80M$129.00M$124.20M
Avg Forecast$485.73M$447.33M$433.30M$399.04M$425.25M$393.15M$378.28M$344.06M$369.12M$331.51M$347.16M$370.09M$339.83M$314.51M$281.55M$336.45M$312.74M$251.64M$233.46M$305.86M$233.45M$207.07M$184.65M$169.74M$185.10M$167.66M$139.45M$171.20M$147.61M$116.44M
High Forecast$500.64M$461.05M$446.60M$411.29M$438.30M$405.21M$389.88M$354.18M$372.48M$331.73M$347.16M$444.11M$350.26M$317.44M$290.18M$403.74M$375.29M$251.64M$233.46M$367.03M$233.45M$207.07M$184.65M$203.69M$185.10M$167.66M$139.45M$205.44M$147.61M$116.44M
Low Forecast$475.98M$438.35M$424.60M$391.03M$416.72M$385.25M$370.68M$340.68M$362.41M$331.29M$347.16M$296.07M$333.01M$311.63M$275.89M$269.16M$250.19M$251.64M$233.46M$244.69M$233.45M$207.07M$184.65M$135.79M$185.10M$167.66M$139.45M$136.96M$147.61M$116.44M
Surprise %------------0.91%0.91%1.06%0.88%0.95%0.93%1.07%0.72%1.01%0.96%1.01%1.11%0.95%0.95%0.98%0.88%0.87%1.07%

DexCom's average Quarter SG&A projection for Mar 24 is $370.09M, based on 1 Wall Street analysts, with a range of $296.07M to $444.11M. The forecast indicates a 19.85% rise compared to DXCM last annual SG&A of $308.80M (Dec 23).

DexCom EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts6446437912611318159101681099139910101099
EPS-------------$0.31$0.30$0.13$0.24$0.26$0.13$0.25$-0.05$0.18$0.16$0.10$0.23$0.19$0.12$0.06$0.25$0.13
Avg Forecast$0.76$0.65$0.58$0.46$0.63$0.54$0.48$0.38$0.50$0.43$0.39$0.27$0.43$0.34$0.23$0.15$0.27$0.24$0.18$0.13$0.22$0.16$0.11$0.08$0.23$0.16$0.08$0.04$0.19$0.05
High Forecast$0.79$0.67$0.60$0.48$0.65$0.56$0.50$0.46$0.56$0.43$0.39$0.27$0.46$0.46$0.23$0.15$0.29$0.24$0.18$0.13$0.22$0.16$0.11$0.08$0.23$0.16$0.08$0.04$0.19$0.05
Low Forecast$0.74$0.63$0.56$0.45$0.61$0.52$0.47$0.31$0.41$0.43$0.39$0.27$0.39$0.26$0.22$0.14$0.27$0.24$0.18$0.13$0.22$0.16$0.11$0.08$0.23$0.16$0.08$0.04$0.19$0.05
Surprise %-------------0.91%1.33%0.89%0.88%1.06%0.71%1.91%-0.23%1.12%1.46%1.36%1.00%1.17%1.46%1.47%1.36%2.50%

According to 3 Wall Street analysts, DexCom's projected average Quarter EPS for Dec 23 is $0.43, with a low estimate of $0.39 and a high estimate of $0.46. This represents a 38.94% increase compared to DXCM previous annual EPS of $0.31 (Sep 23).

DexCom Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
INMDInMode$17.41$26.0049.34%Hold
TNDMTandem Diabetes Care$36.36$51.7142.22%Buy
INSPInspire Medical Systems$189.99$256.0034.74%Buy
DXCMDexCom$86.43$110.0027.27%Buy
ZBHZimmer Biomet$111.05$123.0010.76%Hold
EWEdwards Lifesciences$71.13$75.085.55%Buy
MDTMedtronic$91.41$95.184.12%Hold
PODDInsulet$277.11$268.00-3.29%Buy
BSXBoston Scientific$102.71$97.44-5.13%Buy
ABTAbbott Laboratories$127.86$119.10-6.85%Buy
IARTIntegra LifeSciences$26.12$23.00-11.94%Sell
PENPenumbra$269.73$232.09-13.95%Buy

DXCM Forecast FAQ

Is DexCom a good buy?

Yes, according to 13 Wall Street analysts, DexCom (DXCM) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 10 'Buy' recommendations, accounting for 84.62% of DXCM's total ratings.

What is DXCM's price target?

DexCom (DXCM) average price target is $110 with a range of $100 to $120, implying a 27.27% from its last price of $86.43. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will DexCom stock go up soon?

According to Wall Street analysts' prediction for DXCM stock, the company can go up by 27.27% (from the last price of $86.43 to the average price target of $110), up by 38.84% based on the highest stock price target, and up by 15.70% based on the lowest stock price target.

Can DexCom stock reach $130?

DXCM's average twelve months analyst stock price target of $110 does not support the claim that DexCom can reach $130 in the near future.

What are DexCom's analysts' financial forecasts?

DexCom's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.6B (high $4.74B, low $4.52B), average EBITDA is $866.81M (high $893.16M, low $851.39M), average net income is $829.95M (high $890.46M, low $782.94M), average SG&A $1.54B (high $1.59B, low $1.51B), and average EPS is $2.02 (high $2.17, low $1.91). DXCM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $5.27B (high $5.44B, low $5.17B), average EBITDA is $993.21M (high $1.02B, low $973.27M), average net income is $1B (high $1.04B, low $977.91M), average SG&A $1.77B (high $1.82B, low $1.73B), and average EPS is $2.45 (high $2.55, low $2.38).

Did the DXCM's actual financial results beat the analysts' financial forecasts?

Based on DexCom's last annual report (Dec 2023), the company's revenue was $3.62B, beating the average analysts forecast of $3.52B by 3.00%. Apple's EBITDA was $916.7M, beating the average prediction of $645.78M by 41.95%. The company's net income was $541.5M, missing the average estimation of $557.26M by -2.83%. Apple's SG&A was $1.19B, missing the average forecast of $1.27B by -6.83%. Lastly, the company's EPS was $1.4, beating the average prediction of $1.14 by 22.45%. In terms of the last quarterly report (Dec 2023), DexCom's revenue was $1.03B, beating the average analysts' forecast of $1.02B by 1.89%. The company's EBITDA was $303.6M, beating the average prediction of $191.19M by 58.80%. DexCom's net income was $256.3M, beating the average estimation of $176.68M by 45.06%. The company's SG&A was $308.8M, missing the average forecast of $339.83M by -9.13%. Lastly, the company's EPS was $0, missing the average prediction of $0.431 by -100.00%